In a busy emergency department, the 12-lead electrocardiogram is often the first test a patient with chest pain receives. HEARTio, a Pittsburgh healthtech company founded in 2018, is building software it calls ECGio that aims to help emergency providers identify heart abnormalities in that narrow diagnostic window, with an initial focus on coronary artery disease [Forbes].
The patient population the company is trying to serve is one of the largest in acute medicine: adults presenting to the ER with symptoms that could indicate ischemic heart disease. Today, the standard of care begins with a 12-lead ECG read by an emergency physician, often with an automated interpretation generated by the ECG cart itself, followed by serial high-sensitivity troponin blood tests, structured risk scores, and, when warranted, downstream imaging. The bottleneck is often the interpretation of subtle or non-classical ECG patterns in patients whose troponin has not yet risen.
That is the wedge HEARTio is going after. ECGio is described as an algorithm meant to help doctors detect coronary artery disease faster from the ECG itself [Forbes]. The company's own positioning frames it as fast, accurate, and accessible AI-powered diagnostics for heart health [HEARTio]. According to Forbes, the algorithm is not yet FDA-cleared, but a validation study found it able to identify the disease state the company is targeting [Forbes]. Crunchbase characterizes the company as a digital diagnostics startup using AI to help emergency providers identify heart abnormalities [Crunchbase]. Until a clearance decision is on the record, ECGio sits in the same regulatory bucket as most cardiology AI tools that have come before it: a software-as-a-medical-device candidate that will need a 510(k) pathway before it can be sold into US hospitals for clinical decision-making.
The tailwinds for that bet are real. Cardiology has become one of the most active categories in regulated medical AI, with FDA-cleared ECG algorithms already on the market for atrial fibrillation detection and left ventricular dysfunction screening. Coronary artery disease remains the leading cause of death in the United States, and the missed or delayed ER diagnosis of acute coronary syndrome is a significant source of diagnostic error. The Richard King Mellon Foundation, a major Pittsburgh-based funder, is listed among HEARTio's investors [Dealroom.co], which fits the profile of a mission-aligned capital base willing to support clinical validation work.
The founding team came out of the University of Pittsburgh, where co-founders Adam Butchy, Utkars Jain, and Michael Leasure built the company before being named to the 2024 Forbes 30 Under 30 Healthcare list [Forbes] [University of Pittsburgh]. Jain holds a PhD and is publicly affiliated with HEARTio [LinkedIn]. The company has raised roughly $1.5 million through a combination of angel investments, grants, and competitions [Dealroom.co].
| Metric | Value |
|---|---|
| Total disclosed funding to date | $1.5M |
What the bears would say is that an unblinded validation study is not a pivotal trial, and FDA review timelines for novel cardiology algorithms can stretch past a year. Competitive pressure in ECG-based AI is also intensifying. The bullish counter is that HEARTio's indication is narrower and more clinically actionable than general arrhythmia screening, that a validation study has already shown signal [Forbes], and that the company has been capital-efficient enough to reach that milestone on roughly $1.5 million [Dealroom.co].
The next twelve months are about regulatory posture and clinical evidence. The milestones worth watching are a published peer-reviewed validation of ECGio in a representative ER population, a 510(k) submission or a De Novo pathway filing with the FDA, and a Series A that would give the company the runway to run prospective studies at partner health systems. Pittsburgh has a deep pool of academic medical centers, including UPMC, that have historically served as proving grounds for locally founded health technology, and a named hospital partnership would be a meaningful signal.